OTCMKTS:UCBJF - UCB Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $87.4203 +2.92 (+3.46 %) (As of 11/16/2018 04:00 PM ET)Previous Close$87.4203Today's Range$87.4203 - $87.420352-Week Range$72.78 - $94.30Volume116 shsAverage Volume77 shsMarket Capitalization$16.44 billionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileDiscussionAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. UCB SA was founded in 1928 and is based in Brussels, Belgium. Receive UCBJF News and Ratings via Email Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:UCBJF Previous Symbol CUSIPN/A Webwww.ucb.com Phone32-2559-9999 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio15.81 P/E Growth3.82 Sales & Book Value Annual Sales$4.55 billion Price / Sales3.74 Cash Flow$3.4746 per share Price / Cash25.16 Book Value$31.16 per share Price / Book2.81 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares194,510,000Market Cap$16.44 billion OptionableNot Optionable UCB (OTCMKTS:UCBJF) Frequently Asked Questions What is UCB's stock symbol? UCB trades on the OTCMKTS under the ticker symbol "UCBJF." What is the consensus analysts' recommendation for UCB? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for UCB. Has UCB been receiving favorable news coverage? News articles about UCBJF stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. UCB earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Who are some of UCB's key competitors? Some companies that are related to UCB include Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN) and Ono Pharmaceutical (OPHLF). Who are UCB's key executives? UCB's management team includes the folowing people: Mr. Jean-Christophe Tellier, Chief Exec. Officer and Exec. Director (Age 59)Mr. Detlef Thielgen, CFO & Exec. VP (Age 58)Mr. Charl Van Zyl, COO & Exec. VP (Age 51)Ms. Anna S. Richo, Exec. VP and Gen. Counsel (Age 58)Dr. Bharat Tewarie, Chief Marketing Officer and Exec. VP (Age 57) How do I buy shares of UCB? Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is UCB's stock price today? One share of UCBJF stock can currently be purchased for approximately $87.4203. How big of a company is UCB? UCB has a market capitalization of $16.44 billion and generates $4.55 billion in revenue each year. What is UCB's official website? The official website for UCB is http://www.ucb.com. How can I contact UCB? UCB's mailing address is 60 ALLEE DE LA RECHERCHE, BRUSSELS C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected] MarketBeat Community Rating for UCB (OTCMKTS UCBJF)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 109 (Vote Outperform)Underperform Votes: 126 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote "Outperform" if you believe UCBJF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/17/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?